Home   >  
MAPK Pathway
  >  
Raf

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Raf

Chemical Structure Cat. No. Product Name CAS No.
Encorafenib Chemical Structure
BCP44104 Encorafenib 1269440-29-0
Encorafenib is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells.
Rineterkib hydrochloride Chemical Structure
BCP43938 Rineterkib hydrochloride 1715025-34-5
Rineterkib is a RAF and ERK1/2 inhibitor which has demonstrated preclinical activity in multiple MAPK activated cancer cells and xenograft models.
MCP110 Chemical Structure
BCP43521 MCP110 521310-51-0
MCP110 is an inhibitor of Ras.
Vemurafenib Chemical Structure
BCP43160 Vemurafenib 1029872-54-5
Vemurafenib is a selective inhibitor of BRAF kinase that is used in the therapy of patients with metastatic and advanced malignant melanoma. Vemurafenib therapy is commonly associated with transient elevations in serum aminotransferase during therapy and has been linked to rare, but occasionally severe cases of clinically apparent acute liver injury.
Lifirafenib Chemical Structure
BCP42783 Lifirafenib 1446090-79-4
Lifirafenib is a Novel potent and selective RAF Kinase and EGFR inhibitor.
Rineterkib Chemical Structure
BCP38204 Rineterkib 1715025-32-3
Rineterkib is a RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway.
Donafenib Chemical Structure
BCP34023 Donafenib 1130115-44-4
Donafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib is under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC).
AZ304 Chemical Structure
BCP31900 AZ304 942507-42-8
AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC50s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC50, 6 nM), CSF1R (IC50, 35 nM). Anti-tumor activity.
Belvarafenib Chemical Structure
BCP31233 Belvarafenib 1446113-23-0
Belvarafenib is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.
RO5126766 Chemical Structure
BCP21067 RO5126766 946128-88-7
Ro 5126766 is a first-in-class dual MEK/RAF inhibitor that allosterically inhibits BRAFV600E, CRAF, MEK, and BRAF (IC50: 8.2, 56, 160 nM, and 190 nM, respectively).
123下一页末页共 48 条记录 1 / 5 页 
0086-13720134139